Halcion – Medicinal Product Register of Latvia

Triazolamum

Search by the name of the active substance

Medicinal product name	Halcion 0.125 mg tablets
Pharmaceutical form	Tablet
Strength	0.125 mg
Information from the MAH on shortages	Not notified
Legal status	Rx Prescription (Pr.III)
Package leaflet	28-12-2022
Summary of product characteristics	28-12-2022
ATC code	N05CD05 – Psycholeptics
Information for Marketing authorisation holders	View

Product information leaflet and summary of product characteristics in MS Word format.

Package leaflet	28-12-2022
Summary of product characteristics	28-12-2022

Medicinal products (5)

Display only medicinal products with a declared price

Display only medicinal products available in wholesalers' stock

Availability of medicinal product	Wholesalers	Package size, content	Primary packaging	Product No.	Labelling
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N10 (0,125 mg)	PVC/Al blister	00-0921-01	Labelling text Jul 21, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N30 (0,125 mg)	PVC/Al blister	00-0921-02	Labelling text Jul 21, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N7 (0,125 mg)	PVC/Al blister	00-0921-03	Labelling text Jul 21, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N14 (0,125 mg)	PVC/Al blister	00-0921-04	Labelling text Jul 21, 2020
Not available (according to the information provided by wholesalers)	currently no information on availability from any wholesaler	N100: 10 × 10 (0,125 mg)	PVC/Al blister	00-0921-05	Labelling text Jul 21, 2020

Registration information

Marketing authorisation No.	00-0921
Date of authorisation	Sep 27, 2000
Marketing authorisation holder, country	Pfizer Europe MA EEIG, Belgium

Return to the results

Icon explanation

– Medicine is available
– Medicine is not available
– Distribution permitted for a limited time span
– Without a prescription
– Prescription medicine

– Medicine is listed on the Latvian National Health Service (NHS) list of state reimbursed medicines. (source of the information – the NHS)
– Reference medicine on the NHS List of state reimbursed medicines
– Lowest cost medicine within its therapeutic effectiveness class in cases where no reference medicine is available
- – Next lowest cost medicine after or (in ascending order)

Class A A (green): Suitable for the older persons. The medicinal substance can be used as in younger patients. Changes due to aging do not affect the dose or frequency of administration, and the adverse reaction profile is not different from that of younger patients.

Class B B (grey): There is little research evidence, practical experience or efficacy in older persons.

Class C C (yellow): Suitable for older persons, with specific cautions. The medicinal substance can be used by older persons, but the dose might either have to be reduced, or the frequency of administration decreased due to mild or moderate renal insufficiency or a significant risk of interactions or adverse reactions.

Class D D (red): Avoid use in older persons. Use is possible only in exceptional cases or on a one-off basis. Changes due to aging predispose older persons to adverse or dangerous reactions to the drug. The risk of adverse reactions typically exceeds the benefits.

Meds75+ data source is Finnish Medicines Agency Fimea (licensed under CC BY 4.0).
Data updated on May 31, 2024.